CA2355495A1 - Method of modulating tumor immunity - Google Patents
Method of modulating tumor immunity Download PDFInfo
- Publication number
- CA2355495A1 CA2355495A1 CA 2355495 CA2355495A CA2355495A1 CA 2355495 A1 CA2355495 A1 CA 2355495A1 CA 2355495 CA2355495 CA 2355495 CA 2355495 A CA2355495 A CA 2355495A CA 2355495 A1 CA2355495 A1 CA 2355495A1
- Authority
- CA
- Canada
- Prior art keywords
- regulatory
- cells
- use according
- protein
- ly6a
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract 3
- 230000036039 immunity Effects 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 claims abstract 8
- 210000003289 regulatory T cell Anatomy 0.000 claims abstract 7
- 102000004264 Osteopontin Human genes 0.000 claims abstract 3
- 108010081689 Osteopontin Proteins 0.000 claims abstract 3
- 230000001105 regulatory effect Effects 0.000 claims abstract 3
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 230000004663 cell proliferation Effects 0.000 claims 3
- 238000012258 culturing Methods 0.000 claims 3
- 230000004565 tumor cell growth Effects 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Novel cells and molecules involved in tumor immunity are disclosed.
The novel cells are regulatory T-cells having the phenotype CD3+.alpha..beta.-TcR+CD4-CD8-CD44-CD28-NK1.1-. The regulatory cells express Ly6A and osteopontin while non-regulatory cells do not.
The novel cells are regulatory T-cells having the phenotype CD3+.alpha..beta.-TcR+CD4-CD8-CD44-CD28-NK1.1-. The regulatory cells express Ly6A and osteopontin while non-regulatory cells do not.
Claims (11)
1. A use of an effective amount of (i) a regulatory T-cell having the phenotype CD3+.alpha..beta.-TcR+CD4-CD8-CD44-CD28-NK1.1-, or (ii) an agent that can induce or activate the regulatory T-cell to inhibit tumor cell growth or proliferation.
2. A use according to claim 1 wherein the agent that can induce or activate the regulatory T cell is selected from cytokines, antigens and antibodies that bind the regulatory cells.
3. A use according to claim 1 comprising an effective amount of an antibody that stimulates a regulatory T cell having the phenotype CD3+.alpha..beta.-TcR+CD4-CD8-CD44-CD28-NK1.1-.
4. A use according to claim 1 wherein the regulatory T cells are expanded or activated in vitro prior to their use by culturing the cells with IL-2 and IL-4.
5. A use according to claim 4 further comprising culturing the cells with one class I mismatched allogeneic lymphocytes.
6. A use according to claim 1 wherein the regulatory T cells are expanded or activated in vitro prior to their use by culturing the cells in the presence of an antigen.
7. A use according to any one of claims 1 to 6 to treat or prevent cancer.
8. A use of an effective amount of an Ly6A protein or a nucleic acid sequence encoding an Ly6A protein to inhibit tumor cell growth or proliferation.
9. A use according to claim 8 wherein the Ly6A protein is a soluble fusion protein.
10. A use of an effective amount of an osteopontin or a nucleic acid sequence encoding an Ly6A protein to inhibit tumor cell growth or proliferation.
11. A use according to claim 10 wherein the osteopontin is a soluble fusion protein.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2355495 CA2355495C (en) | 2000-08-21 | 2001-08-21 | Method of modulating tumor immunity |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22657300P | 2000-08-21 | 2000-08-21 | |
| US60/226,573 | 2000-08-21 | ||
| CA002316089A CA2316089A1 (en) | 1999-10-08 | 2000-08-24 | Novel cells and molecules involved in immune regulation |
| CA2,316,089 | 2000-08-24 | ||
| CA 2355495 CA2355495C (en) | 2000-08-21 | 2001-08-21 | Method of modulating tumor immunity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2355495A1 true CA2355495A1 (en) | 2002-02-21 |
| CA2355495C CA2355495C (en) | 2012-04-17 |
Family
ID=27171324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2355495 Expired - Fee Related CA2355495C (en) | 2000-08-21 | 2001-08-21 | Method of modulating tumor immunity |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2355495C (en) |
-
2001
- 2001-08-21 CA CA 2355495 patent/CA2355495C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2355495C (en) | 2012-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dainiak et al. | Methods in cell separations | |
| WO2003083069A3 (en) | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing cd3 or 4-1bb | |
| GR3036951T3 (en) | Cells with multiple altered epitopes on a surface antigen for use in transplantation | |
| NZ333607A (en) | Method of stimulating the immune system by transfecting dendritic cells | |
| CA2211147A1 (en) | A method of preparing an undifferentiated cell | |
| DE69328481T2 (en) | IN VITRO FORMATION OF DENTRITIC CELLS | |
| Eggermont et al. | Cytokine‐functionalized synthetic dendritic cells for T cell targeted immunotherapies | |
| De Matteis et al. | Immunosuppressive Treg cells acquire the phenotype of effector-T cells in chronic lymphocytic leukemia patients | |
| GB9424631D0 (en) | Modulating the immune response | |
| Marino et al. | The capacity of activated murine macrophages for augmented binding of neoplastic cells: analysis of induction by lymphokine containing MAF and kinetics of the reaction. | |
| AU2002223462A1 (en) | Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28 | |
| Maki | Ex vivo purging of stem cell autografts using cytotoxic cells | |
| WO1995024481A3 (en) | Humanized monoclonal antibodies against human interleukin-4 | |
| CA2355495A1 (en) | Method of modulating tumor immunity | |
| EP0160486A3 (en) | Monoclonal antibodies | |
| NO965087L (en) | Isolated nucleic acid molecule encoding a tumor rejection antigen precursor, and use thereof | |
| Bertolini et al. | A new ‘two step’procedure for 4.5 log depletion of T and B cells in allogeneic transplantation and of neoplastic cells in autologous transplantation | |
| AU645488B2 (en) | A process for the generation of proliferating CD4 lymphocytes | |
| ATE322540T1 (en) | PREPARATION FOR TRANSFER OF ACTIVE TUMOR-SPECIFIC IMMUNIZATION FROM AN IMMUNIZED ALLOGENEIC BONE MARROW DONOR | |
| AU6659390A (en) | Methods for utilizing cell lines which lack human class ii histocompatibility antigens | |
| Huber et al. | Activation of phenotypically heterogeneous murine T cell receptor γδ+ dendritic epidermal T cells by self-antigen (s) | |
| Paque | RNA as a biological response modifier: a reassessment | |
| Bensinger | 4 Isolating stem and progenitor cells W. BENSINGER | |
| RU2004131559A (en) | ACTIVATION OF TUMOR-REACTIVE LYMPHOCYTES ANTIBODIES OR GENES RECOGNIZING CD3 OR 4-1BB | |
| CHUA | AN INVESTIGATION ON THE SURFACE PROPERTIES OF EMBRYONAL CARCINOMA CELLS: FUNCTIONAL AND STRUCTURAL CORRELATIONS TO EARLY EMBRYOS (GLYCOPROTEINS, PREIMPLANTATION, MOUSE) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20180821 |